Regulatory Status (UK)

Retatrutide is an unauthorised investigational substance in the UK. It is not a controlled drug, but as an unauthorised medicinal substance it cannot be supplied, advertised or used for human or veterinary purposes.

Last editorial review: 2026-09-18 · Part of the Retatrutide research hub

Two separate legal questions

Researchers usually want to know two things: whether the substance is controlled, and whether it may be supplied for use in people. Retatrutide is not listed as a controlled drug, but it also holds no marketing authorisation, which is what prohibits supply for human use.

Those two answers are independent. A substance can be entirely outside drug-control legislation and still be unlawful to sell for consumption.

Obligations that fall on the supplier

A compliant research supplier does not make therapeutic claims, does not give dosing guidance, does not present the material as a medicine, and labels every vial for research use only. Marketing that implies human use converts a lawful research sale into an unlawful medicinal one.

Obligations that fall on the laboratory

Receiving laboratories are responsible for local risk assessment, competent handling, appropriate storage and correct disposal, and for keeping the material within an in-vitro research context.

This page is general research information about regulatory status. It is not legal advice; where a specific situation matters, take advice on your own facts.

Retatrutide supplied by Biovanta Research is laboratory material for in-vitro research by qualified persons. It is not a medicine, not for human or veterinary use, and no dosing guidance is given.

How to verify each part of this position independently

Control status under UK drugs legislation can be checked against the schedules referenced by the Home Office and against published guidance, while medicinal authorisation status is checked directly in the MHRA products register described elsewhere in this cluster. Because these are two independent legal questions, verifying one does not verify the other, and a laboratory should not assume that absence from a controlled-drug schedule implies any form of authorisation for human use, or vice versa.

Common misconceptions about legal status

A frequent misunderstanding is that ‘not a controlled drug’ is equivalent to ‘legal to use in people’. It is not: an unauthorised medicinal substance can be entirely lawful to possess and use for in-vitro research while still being unlawful to supply, advertise or administer for human use. Another misunderstanding is that research-use-only labelling is a formality; in practice it is the labelling that keeps a sale within the lawful research-supply category rather than the unlawful medicinal-supply category, so it is a substantive legal boundary, not decorative text.

What would change this position

This summary would need to be revisited if UK drug-control schedules were amended to include retatrutide, or if the MHRA granted a marketing authorisation for a retatrutide-containing product, either of which would be publicly announced and reflected in the relevant register. Absent either event, the position described here should be treated as stable, though it is good practice to re-check the primary sources periodically rather than rely solely on this summary.

How this differs from the position in the United States

The general shape of the position is similar in the United States, where retatrutide is likewise not a scheduled controlled substance but is also not FDA approved, so supply for human use is restricted under US drug law rather than controlled-substance law. The specific legal mechanisms differ between the two jurisdictions, including the bodies responsible for enforcement and the precise statutory basis for restricting supply, so a statement of US legal position should not be assumed to describe the UK position, or vice versa, even where the practical outcome, that human use is not lawfully supplied, is the same in both.

What a laboratory should keep on file to demonstrate compliant use

A UK laboratory using retatrutide as research material should be able to show, if asked, that the material was purchased under research-use-only terms, that it has not been supplied onward for human use, that it is stored and handled under the laboratory’s own risk assessment, and that its research-use-only labelling has been preserved. Keeping the original certificate of analysis and purchase record alongside this documentation is a reasonable minimum standard and mirrors the kind of record a regulator or auditor would expect to see for any unauthorised research chemical.

Strength of the current evidence

Authorisation status is verifiable in the MHRA register. The control status statement reflects the absence of retatrutide from UK controlled-drug schedules on the review date, and both should be periodically re-checked against their primary sources.

References

1. MHRA public assessment reports and product information (MHRA)
2. FDA Drugs@FDA approved drug products database (FDA)

Related Retatrutide research

• Retatrutide in the UK — Supply, testing and dispatch context for retatrutide research material in the United Kingdom.
• What is Retatrutide? — Definition, research designation, peptide class and receptor targets of retatrutide as a laboratory research compound.
• Is Retatrutide Approved? — Current regulatory status of retatrutide: investigational, not approved as a medicine in the UK, US or EU.

Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis

Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.